SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT06266871
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
64
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
SOX+Tislelizumab+LDRT
Sponsor
West China Hospital